US Patent

US7579456 — Aptamer therapeutics useful in the treatment of complement-related disorders

Composition of Matter · Assigned to Archemix Corp · Expires 2027-02-14 · 1y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a nucleic acid therapeutic for treating complement-related disorders.

USPTO Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: US7579456
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-02-14
Drug substance claim: Yes
Drug product claim: No
Assignee: Archemix Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.